Development of covalently bound hyaluronic acid as an adjuvant for multivalent lyme disease vaccine
Active Definitive Contract Awarded Last action
- Contract number
- 75N93024C00016
- Awardee
-
Design-Zyme LLC UEI RM33XDX5RRG4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,999,999
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20241 · Posted Jul 7, 2023
- Contract value 100% obligated
- $2,999,999.00 Current and potential, with all options
- Completion date 70% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 16 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Lawrence, KS 66047, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $2,999,999 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $2.999 million definitive contract to Design-Zyme LLC for development of covalently bound hyaluronic acid as an adjuvant for multivalent Lyme disease vaccine on September 30, 2024, under a total small business set-aside.
The contract is firm fixed price with an ultimate completion date of September 29, 2027. Place of performance is Lawrence, KS. The originating pre-solicitation, posted July 7, 2023 with a November 7, 2023 due date, sought innovative adjuvant development to support next-generation Lyme disease vaccine formulations. This award reflects NIAID's investment in novel immunological platforms for tick-borne disease prevention.
Quick answers
Who was awarded contract 75N93024C00016?
75N93024C00016 was awarded to Design-Zyme LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 17, 2024.
How much is contract 75N93024C00016 worth?
The government has obligated $2,999,999 on 75N93024C00016.
Was contract 75N93024C00016 competed?
The extent of competition for 75N93024C00016 was full and open competition after exclusion of sources. The government received 16 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award